Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 601 AL 615

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA.

Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10.

How Parkinson's disease meets nucleolar stress

Parlato R, Liss B.

Biochim Biophys Acta. 2014 Jun;1842(6):791-7. doi: 10.1016/j.bbadis.2013.12.014. Epub 2014 Jan 8.

Management of faecal incontinence and constipation in adults with central neurological diseases

Coggrave M, Norton C, Cody JD.

Cochrane Database Syst Rev. 2014 Jan 13;2014(1):CD002115. doi: 10.1002/14651858.CD002115.pub5.

Thin-slice judgments in the clinical context

Slepian ML, Bogart KR, Ambady N.

Annu Rev Clin Psychol. 2014;10:131-53. doi: 10.1146/annurev-clinpsy-090413-123522. Epub 2014 Jan 9.

Vertebrobasilar territory ischemic stroke after electrical injury: delayed sequelae

Jain RS, Gupta PK, Handa R, Nagpal K, Prakash S, Agrawal R.

J Stroke Cerebrovasc Dis. 2014 Jul;23(6):1721-3. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.023. Epub 2014 Jan 11.

Perazine for schizophrenia

Leucht S, Helfer B, Hartung B.

Cochrane Database Syst Rev. 2014 Jan 15;2014(1):CD002832. doi: 10.1002/14651858.CD002832.pub3.

Novel levodopa formulations in the treatment of Parkinson's disease

Pilleri M, Antonini A.

Expert Rev Neurother. 2014 Feb;14(2):143-9. doi: 10.1586/14737175.2014.877840. Epub 2014 Jan 13.

Vitamin D as a potential therapy in amyotrophic lateral sclerosis

Gianforcaro A, Hamadeh MJ.

CNS Neurosci Ther. 2014 Feb;20(2):101-11. doi: 10.1111/cns.12204.

Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease

L'Episcopo F, Tirolo C, Caniglia S, Testa N, Morale MC, Serapide MF, Pluchino S, Marchetti B.

J Mol Cell Biol. 2014 Feb;6(1):13-26. doi: 10.1093/jmcb/mjt053. Epub 2014 Jan 14.

Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease

Arenas E.

J Mol Cell Biol. 2014 Feb;6(1):42-53. doi: 10.1093/jmcb/mju001. Epub 2014 Jan 14.

Non-motor symptoms of Parkinson's disease A review…from the past

Garcia-Ruiz PJ, Chaudhuri KR, Martinez-Martin P.

J Neurol Sci. 2014 Mar 15;338(1-2):30-3. doi: 10.1016/j.jns.2014.01.002. Epub 2014 Jan 8.

Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study

Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):840-4. doi: 10.1136/jnnp-2013-306787. Epub 2014 Jan 16.

Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study

Eggert K, Oertel WH, Lees AJ; German Competence Network on Parkinson’s disease.

Clin Neuropharmacol. 2014 Jan-Feb;37(1):1-5. doi: 10.1097/WNF.0000000000000008.

Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study

Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, van Laar T, Storch A, Micheli F, Burn D, Durif F, Pahwa R, Callegari F, Tenenbaum N, Strohmaier C.

Clin Neuropharmacol. 2014 Jan-Feb;37(1):9-16. doi: 10.1097/WNF.0000000000000010.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias